You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
Kedrion Biosc - Front Image


  1. 29-03-2018

    Annual Results 2017

    Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%

    read more 
  2. 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells

    read more 
  3. 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  4. 11-08-2017

    First half results 2017

    First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%

    read more 
  5. 12-07-2017

    Result of cash tender offer for Notes due 24 april 2019

    The Company hereby announces to accept for purchase Notes validly tendered pursuant to the Offer for a total aggregate principal amount equal to €91,080,000

    read more 
  6. 05-07-2017

    Launch of new 350 Million Bond and tender offer indicative results

    Kedrion successfully completed pricing of new Euro 350 M notes due July 2022 and tender offer for notes due April 2019

    read more 
  7. 27-06-2017

    Cash Tender Offer for Notes due 24 April 2019

    Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019

    read more 
  8. 27-04-2017

    Audited financial statements 2016

    Kedrion’s shareholders meeting approved the 2016 stand-alone Financial Statements and acknowledged the 2016 Consolidated FS

    read more 
  9. 31-03-2017

    Annual Results 2016

    Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%

    read more 


For more information please contact: